Research programme: Alzheimer's disease therapeutics - SenexisAlternative Names: SEN1176; SEN1500; SEN1576; SEN304; SEN606
Latest Information Update: 22 Feb 2011
At a glance
- Originator Senexis
- Class Peptides; Small molecules
- Mechanism of Action Amyloid beta-protein inhibitors; Macrophage inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Alzheimer's disease